Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants
Alberto Zani, Francesca Caccuri, Serena Messali, Carlo Bonfanti, Arnaldo Caruso
Abstract
In this study, we show that BNT162b2 vaccine-elicited antibodies efficiently neutralize SARS-CoV-2 authentic viruses belonging to B.1, B.1.1.7, B.1.351, B.1.525 and P.1 lineages. Interestingly, the neutralization of B.1.1.7 and B.1.525 lineages was significantly higher, whereas the neutralization of B.1.351 and P.1 lineages was robust but significantly lower as compared to B.1 lineage. Following our findings, we consider that the BNT162b2 vaccine offers protection against the current prevailing variants of SARS-CoV-2.
Topics & Concepts
NeutralizationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyAntibodyCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakNeutralizing antibodySpike ProteinMedicineBiologyImmunologyOutbreakPathologyInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral gastroenteritis research and epidemiology